Dynavax Technologies | DVAX - Current Liabilities


Dynavax Technologies reported $106.84M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
AbbVie USD 39.39B 376M Sep/2025
Adma Biologics USD 56.49M 18.45M Sep/2025
Amgen USD 21.79B 1.32B Sep/2025
AstraZeneca USD 34.05B 518M Sep/2025
Biogen USD 3.29B 106.3M Sep/2025
BioMarin Pharmaceutical USD 798.44M 114.19M Sep/2025
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Dynavax Technologies USD 106.84M 11.39M Sep/2025
Gilead Sciences USD 12.3B 1.11B Sep/2025
Glaxosmithkline GBP 28.68B 8.3B Sep/2025
Merck USD 28.63B 2.59B Sep/2025
Neurocrine Biosciences USD 638M 91.7M Sep/2025
Novartis USD 32B 286M Sep/2025
Pfizer USD 36.6B 1.13B Sep/2025
Regeneron Pharmaceuticals USD 4.43B 758.1M Sep/2025
Roche Holding CHF 28B 421M Dec/2025
Sarepta Therapeutics USD 921.42M 1.48M Sep/2025
TG Therapeutics USD 156.81M 15.08M Sep/2025
Vertex Pharmaceuticals USD 4.48B 336.9M Sep/2025